ToleroMune Ragweed: Phase II started

Circassia began a double-blind, placebo-controlled, Canadian Phase II trial to evaluate 2 doses of its bi-weekly intradermal ToleroMune Ragweed therapy for 14 weeks in 275 patients following challenge...